Treatment of prostate cancer with gonadotropin-releasing hormone agonists

…, R St-Arnaud, M Giguere, Y Lacourciere… - Endocrine …, 1986 - academic.oup.com
IT IS now well established that chronic treatment with GnRH agonists offers an advantageous
alternative to orchiectomy and estrogens for the treatment of prostate cancer. Castration …

Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial

…, JD Neaton, RH Grimm Jr, L Hansson, Y Lacourcière… - Jama, 2003 - jamanetwork.com
ContextHypertensive patients are often given a calcium antagonist to reduce cardiovascular
disease risk, but the benefit compared with other drug classes is controversial.ObjectiveTo …

The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension

H Krum, RJ Viskoper, Y Lacourciere… - … England Journal of …, 1998 - Mass Medical Soc
Background Endothelin is a powerful vasoconstrictor peptide derived from the endothelium.
We evaluated the contribution of endothelin to blood-pressure regulation in patients with …

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled …

LM Ruilope, A Dukat, M Böhm, Y Lacourcière, J Gong… - The Lancet, 2010 - thelancet.com
Background LCZ696 is a first-in-class inhibitor of the angiotensin II receptor and neprilysin.
We aimed to establish whether the dual actions of LCZ696 lead to further lowering of blood …

[HTML][HTML] β-Blockers in hypertension: studies and meta-analyses over the years

P Larochelle, SW Tobe, Y Lacourcière - Canadian Journal of Cardiology, 2014 - Elsevier
… The role of β-blockers was also reviewed recently by Poirier and Lacourcière, who concluded
that although β-blockers are clearly effective in reducing BP, the mechanism of action of …

New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.

…, A Belanger, L Cusan, Y Lacourciere… - … . Medecine clinique et …, 1982 - europepmc.org
In order to block the influence of androgens from all sources on the growth of prostatic cancer,
we have used a new hormonal therapy based on medical castration achieved with the …

Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial

…, M Bourgoun, WL Daley, D Purkayastha, Y Lacourcière… - The Lancet, 2007 - thelancet.com
Background Diastolic dysfunction might represent an important pathophysiological intermediate
between hypertension and heart failure. Our aim was to determine whether inhibitors of …

Determinants of elevated pulse pressure in middle-aged and older subjects with uncomplicated systolic hypertension: the role of proximal aortic diameter and the …

GF Mitchell, Y Lacourcière, JP Ouellet, JL Izzo Jr… - Circulation, 2003 - Am Heart Assoc
Background— Elevated pulse pressure (PP) is associated with increased cardiovascular risk
and is thought to be secondary to elastin fragmentation with secondary collagen deposition …

Aftereffects of exercise on regional and systemic hemodynamics in hypertension.

…, N Kouame, A Nadeau, D Coulombe, Y Lacourciere - …, 1992 - Am Heart Assoc
Several studies have indicated that a single bout of physical exercise induced a significant
antihypertensive effect during the hours after the activity. However, little information is …

[HTML][HTML] Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy

Y Lacourcière, A Bélanger, C Godin, JP Hallé, S Ross… - Kidney international, 2000 - Elsevier
… Data from Lacourcière et al 7 and Chan et al 18 were used for the power calculation. The
calculation was carried out on the variable defined as LOG 10 (UAE at exit/UAE at baseline). …